Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
LATEST POSTS
- 1
Thousands of New York City nurses set to strike Monday if deal isn't reached with hospitals - 210 Picturesque Campgrounds That Will Raise Your Outside Involvement with American
- 3Greenland’s melting ice and landslide-prone fjords make the oil and minerals Trump is eyeing dangerous to extract
- 4Israel says soldiers wounded in Gaza fighting amid fragile truce
- 519 Peculiar Films You Shouldn't Watch With Your Mum
- Craig the beer-ambassador elephant dies aged 54
- Unraveling the Specialty of Picking Your Ideal Travel Objective
- Support Your Wellness: 20-Minute Home Exercises That Work
- 5 Great Youngster Care Administrations To Watch in 2024
- Sought-After Extravagance Ocean side Objections for a Lovely Escape
- Grammy nominations 2026: Full list of nominees in every major category, including Album of the Year and Best New Artist
- As tetanus vaccination rates decline, doctors worry about rising case numbers
- Key Business Regulations to Consider While Arranging Your Independent venture
- Opening Achievement: 8 Methodologies for Compelling Using time productively
